Stockreport

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Cocrystal Pharma, Inc.  (COCP) 
NASDAQ:AMEX Investor Relations: cocrystalpharma.com
PDF CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy [Read more]